Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

LA Jolla Pharma (LJPC)

LA Jolla Pharma (LJPC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,861
  • Shares Outstanding, K 27,362
  • Annual Sales, $ 23,050 K
  • Annual Income, $ -116,510 K
  • 60-Month Beta 2.43
  • Price/Sales 4.26
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.62
  • Number of Estimates 2
  • High Estimate -0.50
  • Low Estimate -0.74
  • Prior Year -1.08
  • Growth Rate Est. (year over year) +42.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.41 +8.80%
on 08/12/20
4.86 -23.66%
on 07/17/20
-0.43 (-10.39%)
since 07/13/20
3-Month
3.41 +8.80%
on 08/12/20
7.59 -51.12%
on 05/19/20
-3.18 (-46.15%)
since 05/13/20
52-Week
2.30 +61.30%
on 11/26/19
11.41 -67.48%
on 09/11/19
-5.57 (-60.02%)
since 08/13/19

Most Recent Stories

More News
La Jolla Pharmaceutical: 2Q Earnings Snapshot

SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Thursday reported a loss of $15.6 million in its second quarter.

LJPC : 3.71 (+4.80%)
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases,...

LJPC : 3.71 (+4.80%)
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer.

LJPC : 3.71 (+4.80%)
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases,...

LJPC : 3.71 (+4.80%)
TTPH : 2.20 (-3.51%)
SmarTrend Watching for Potential Rebound in Shares of La Jolla Pharm After 4.37% Loss

La Jolla Pharm (NASDAQ:LJPC) traded in a range yesterday that spanned from a low of $4.81 to a high of $5.18. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $4.91...

LJPC : 3.71 (+4.80%)
How La Jolla (LJPC) Stock Stands Out in a Strong Industry

La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

LJPC : 3.71 (+4.80%)
Shares of LJPC Up 50.2% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for La Jolla Pharm (NASDAQ:LJPC) on March 26th, 2020 at $4.96. In approximately 1 month, La Jolla Pharm has returned 50.20% as of today's recent price of $7.45.

LJPC : 3.71 (+4.80%)
La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Lags Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?...

LJPC : 3.71 (+4.80%)
La Jolla Pharmaceutical: 1Q Earnings Snapshot

SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Monday reported a loss of $8.6 million in its first quarter.

LJPC : 3.71 (+4.80%)
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2020

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases,...

LJPC : 3.71 (+4.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade LJPC with:

Business Summary

LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.

See More

Key Turning Points

2nd Resistance Point 3.87
1st Resistance Point 3.79
Last Price 3.71
1st Support Level 3.56
2nd Support Level 3.41

See More

52-Week High 11.41
Fibonacci 61.8% 7.93
Fibonacci 50% 6.86
Fibonacci 38.2% 5.78
Last Price 3.71
52-Week Low 2.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar